Table 1.
Baseline patient demographics
| Overall | Delayed ipilimumab arm | Immediate ipilimumab arm | p value | ||
| n | 50 | 26 | 24 | ||
| Age | (Median (range)) | 67.50 (51.00, 79.00) | 67.00 (57.00, 77.00) | 68.00 (51.00, 79.00) | 0.961 |
| Race (%) | Asian | 3 (6.8) | 1 (4.3) | 2 (9.5) | 0.607 |
| Black or African–American | 3 (6.8) | 1 (4.3) | 2 (9.5) | ||
| White | 38 (86.4) | 21 (91.3) | 17 (81.0) | ||
| NA | 6 (12.0) | 3 (11.5) | 3 (12.5) | ||
| Ethnicity (%) | Hispanic or Latino | 4 (10.0) | 2 (9.5) | 2 (10.5) | 1 |
| Non-Hispanic | 36 (90.0) | 19 (90.5) | 17 (89.5) | ||
| NA | 10 (20.0) | 5 (19.2) | 5 (20.8) | ||
| Gleason score at diagnosis (%) | 7 | 19 (38.8) | 8 (30.8) | 11 (47.8) | 0.353 |
| >7 | 30 (61.2) | 18 (69.2) | 12 (52.2) | ||
| NA | 1 (2.0) | 0 (0.0) | 1 (4.2) | ||
| ECOG Performance Status (%) |
0 | 42 (84.0) | 24 (92.3) | 18 (75.0) | 0.2 |
| 1 | 8 (16.0) | 2 (7.7) | 6 (25.0) | ||
| Site of disease (%) | Lymph node only | 8 (16.0) | 5 (19.2) | 3 (12.5) | 0.673 |
| Bone with or without lymph node | 37 (74.0) | 20 (76.9) | 17 (70.8) | ||
| Any visceral | 5 (10.0) | 1 (3.8) | 4 (19.0) | ||
| Prior treatment (%) | Radical prostatectomy | 6 (12.0) | 3 (11.5) | 3 (12.5) | 0.848 |
| Radiation therapy | 14 (28.0) | 8 (30.8) | 6 (25.0) | ||
| Both | 20 (40.0) | 11 (42.3) | 9 (37.5) | ||
| Neither | 10 (20.0) | 4 (15.4) | 6 (25.0) | ||
| PSA | (Median (range)) | 6.26 (0.10, 311.60) | 8.62 (0.25, 83.74) | 5.68 (0.10, 311.60) | 0.485 |
| Alkaline phosphatase | (Median (range)) | 81.50 (37.00, 257.00) | 83.00 (37.00, 173.00) | 80.50 (39.00, 257.00) | 0.963 |
| Lactate dehydrogenase | (Median (range)) | 136.00 (56.00, 402.00) | 83.50 (56.00, 111.00) | 172.00 (109.00, 402.00) | 0.121 |
| Hemoglobin | (Median (range)) | 12.80 (10.90, 14.60) | 12.80 (11.30, 14.60) | 12.90 (10.90, 14.50) | 0.394 |
PSA, prostate-specific antigen.